Hematopoiesis & Hematologic Malignancies
The goal of the Hematopoiesis and Hematologic Malignancies (HHM) research program is to enhance treatment of hematologic malignancies -- with a focus on leukemia, pre-leukemia, and multiple myeloma -- through rigorous basic mechanistic scientific laboratory efforts, including in vitro cell culture and in vivo pre-clinical animal studies using mouse and human cells.
The program has two themes:
Theme 1: Hematopoiesis (H)
- Aim 1. To better understand the mechanistic regulation of human and mouse hematopoietic stem cells (HSC) and progenitor cells (HPC).
- Aim 2. To increase engraftment and mobilization of HSCs and HPCs.
- Aim 3. To identify novel biomarkers and how to modulate Graft vs. Host Disease (GVHD) for more effective HCT.
Theme 2: Hematologic Malignancies (HM)
- Aim 1. To clarify the cellular and intracellular signaling of Hematologic (i.e. leukemia, myeloma) Malignancies.
- Aim 2. To better understand the relationship of Hematologic Malignancies and the bone microenvironment.